| 4 Severe 0 0 1 0 4 0 | Systemic reactions in persons aged 18-55 years, Pfizer-BioNTech COVID-19 vaccine and placebo Table 3 |
|---|---|
| Most cases of lymphadenopathy resolved in 10 days or less | bMild: does not interfere with activity; moderate: interferes with activity; severe: prevents daily activity; Grade 4: emergency room visit or hospitalization for severe pain at the injection site |
cMild: 2 to 3 loose stools in 24 hours; moderate: 4 to 5 loose stools in 24 hours; severe: 6 or more loose stools in 24 hours; Grade 4: emergency room visit or hospitalization for severe diarrhea.
11| Fatigue, headache, chills, and new or worsened muscle pain were most common | Vomiting and diarrhea were exceptions, and similar between vaccine and placebo groups and regardless of dose |
|---|---|
| 7 Severe 0 0 1 0 | However, their reactions to vaccination are expected to be similar to those of young adults who were included |
| 6 a Mild: does not interfere with activity; moderate: some interference with activity; severe: prevents daily activity; Grade 4: emergency room visit or hospitalization for severe fatigue, severe headache, severe muscle pain, or severe joint pain | Overall, the median onset of local reactions in the vaccine group was 0 day of vaccination to 2 days after either dose and lasted a median duration between 1 and 2 days |
|---|---|
| Systemic Reactions Among all vaccine recipients asked to complete diaries of their symptoms during the 7 days after vaccination, 77 | For more information on CDC's web notification policies, see |
Within each age group, the frequency and severity of systemic adverse events was higher after dose 2 than dose 1.
27